Laser Medical Technology
This article was originally published in The Gray Sheet
Eurocapital Ltd. places 1,209,000 shares of firm's stock, formerly owned by company founder Guy Levy and his son Francois Levy, "into the hands of long-term investors." The transaction, which severs "all working relationship with the Levy family," is significant "because Dr. Levy and his sons have been the only important suppliers of stock in the marketplace, particularly in the past few months," Laser Medical says. As a condition of the placement, Eurocapital asked Dr. Levy to sell back to the company his patent royalty agreement expiring in 2010, valued at $84,000 a year plus cost of living adjustment, in exchange for a one time payment of $100,000. Dr. Levy received "50,000 shares with certain restrictions, and an option to buy three lasers at the current distributor price" as part of the transaction. The firm said the deal will result in an extraordinary gain of more than $400,000 for the first quarter ending in March.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.